Cytek Biosciences, Inc. (CTKB) stock

CTKBNasdaqLaboratory Analytical InstrumentsFiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 8/308% below fair value

$5.84+0.32 (+5.80%)

Close on Nov 13, 2026Market cap $759.10MP/E –Yield –

Cytek Biosciences EV/EBITDA

EV/EBITDA is enterprise value divided by EBITDA over the trailing twelve months.

Cytek Biosciences's EV/EBITDA was 695.6× on Jan 31, 2023, against 95.6× a year earlier.

Period	Period end	Value	Change (pts)
2023	Jan 31, 2023	695.6×	+134.5
2022	Dec 30, 2022	561.1×	+451.2
2021	Dec 31, 2021	109.9×	–

Parsed from the XBRL in Cytek Biosciences's annual and quarterly filings with the SEC
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is CTKB.

Revenue growth5.5% · median 2.5%

Gross margin54.7% · median 57.4%

Operating margin-21.1% · median -11.7%

Net margin-39.1% · median -13.2%

Advertisement
300 × 250

See a number that looks wrong?